Madrigal Q3 Rezdiffra sales rise 50% to $431.3 million; company posts first quarterly profit
Madrigal Pharmaceuticals reported third-quarter 2026 results, with net revenues of $431.3 million, up 50% from $287.3 million a year earlier, driven by U.S. demand for Rezdiffra. The company reported net income of $55.4 million, or $1.83 per diluted share, compared with a net loss of $114.2 million in the prior-year period.
Key points
- Q3 2026 net revenues were $431.3 million, up 50% from $287.3 million in Q3 2025.
- Q3 2026 net income was $55.4 million, or $1.83 per diluted share, versus a net loss of $114.2 million, or $4.01 per share, a year earlier.
- Cash, cash equivalents, restricted cash and marketable securities were $961.8 million as of Sept. 30, 2026, compared with $988.6 million on Dec. 31, 2025.
- Cost of sales rose to $37.8 million from $18.1 million, mainly due to higher royalties payable to Roche; the prior-year R&D figure included a one-time $117.3 million business development expense.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.